“Removed from the boxed warning”: what changed—and what it means for you

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 8, 2026 · Updated November 8, 2026

Two hormone therapy stories are sharing the spotlight: FDA labeling changes and a Swedish brain-scan study being discussed as evidence that estrogen protects the brain.

The label changes are documented, and the study raises worthwhile research questions. Neither means hormone therapy is risk-free—or that it should be prescribed to prevent dementia.

What changed in the boxed warning?

A boxed warning is the FDA’s most prominent safety warning in a medicine’s prescribing information.

The FDA requested removal of statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning of menopausal hormone therapy products, along with other labeling updates.

As of November 8, the FDA lists approved updated labeling for nine products:

• Systemic estrogen alone: Divigel, Cenestin, Enjuvia, Minivelle, Vivelle and Vivelle-Dot.
• Systemic estrogen plus progestogen: Bijuva.
• Progestogen alone: Prometrium.
• Vaginal estrogen: Estring.

These products are not interchangeable. They differ in formulation, route and intended use. If your medicine is not listed, ask your pharmacist or clinician whether its labeling has changed.

What did not change?

Removing information from a boxed warning does not mean removing every risk.

The FDA did not request removal of cardiovascular disease and breast cancer risk information from the Warnings and Precautions section. A different placement in the label is not a declaration that those risks no longer matter.

The FDA also is not requesting removal of the endometrial-cancer boxed warning for systemic estrogen-alone products. Separately, people with a uterus who use systemic estrogen typically need a progestogen to help protect the uterine lining. Your clinician should explain which regimen fits your situation.

Most importantly, updated labeling does not replace an individualized decision. Your symptoms, age, time since menopause, medical history and preferences still matter.

What about the brain–estrogen study?

The study published November 4 in Neurology examined 352 cognitively unimpaired Swedish women from the Gothenburg H70 cohort. Researchers assessed brain MRI findings around age 70, with repeat scans five years later for many participants.

A longer reproductive lifespan and a history of menopausal hormone therapy use were associated with fewer MRI signs of cerebral small-vessel disease—changes involving the brain’s small blood vessels.

That is interesting. It is not proof of prevention.

Three limitations are especially important:

• It was observational. An association cannot establish that hormone therapy caused the difference. Other differences between participants may help explain the findings.
• Hormone-use information was limited. Use was classified as “ever” or “never”; the study could not reliably answer questions about specific doses, routes, duration or starting time.
• MRI findings are not proof of dementia prevention. The study does not establish that starting hormone therapy prevents Alzheimer’s disease, dementia or small-vessel disease.

The authors frame the findings as contributing to “mechanistic understanding rather than immediate clinical translation.” In everyday terms: useful research, not a new prescribing instruction.

We discussed the study in our November 5 explainer and November 6 follow-up.

What should guide a treatment decision?

The American College of Obstetricians and Gynecologists’ October guidance emphasizes shared decision-making: weighing bothersome symptoms, expected benefits, risks and personal priorities with a clinician.

For people choosing hormone therapy, ACOG recommends starting before age 60 or within 10 years of the start of spontaneous menopause, without contraindications to hormone use. That timing guidance is not a guarantee of safety or a recommendation that everyone should take hormones.

Systemic hormone therapy can carry risks including blood clots and stroke; some estrogen-plus-progestogen regimens also increase breast-cancer risk. Common reasons not to use systemic hormone therapy include a history of blood clots, stroke, a current or past heart attack, breast cancer, liver disease, or unexplained vaginal bleeding. These are not the only considerations, and local vaginal treatments have different uses and risk profiles. Your clinician should review your specific medicine and history. Decisions about continuing or stopping treatment are individualized too.

The goal is to treat your symptoms appropriately—not to prescribe from a headline.

When hormones are not the right fit

Some people cannot use hormones or prefer another approach. Nonhormonal treatments are available for moderate to severe hot flashes and night sweats.

Two options have their own safety requirements:

• Fezolinetant, sold as Veozah, carries a boxed warning for serious liver injury. Its label requires liver tests before treatment, monthly for the first three months, and at six and nine months; additional testing may be needed. It must not be used by people with cirrhosis, severe kidney impairment or kidney failure, or with medicines called CYP1A2 inhibitors.
• Elinzanetant, sold as Lynkuet, requires liver tests before treatment and at three months. Its label warns about sleepiness and daytime impairment: do not drive or do hazardous activities if affected until those effects resolve. It also warns about seizures and calls for caution in people with a seizure history or conditions that lower the seizure threshold. It must not be used during pregnancy because it may cause pregnancy loss or stillbirth. Pregnancy must be ruled out before treatment in people who could become pregnant, who should use effective contraception during treatment and for two weeks afterward; stop treatment if pregnancy is confirmed.

Both labels direct patients to stop the medicine immediately and seek medical attention if symptoms suggest liver injury, such as yellow skin or eyes, dark urine, pale stools, itching, unusual tiredness, nausea or abdominal pain. Abnormal baseline liver tests may prevent starting either medicine. A clinician or pharmacist must check other medicines and relevant liver or kidney conditions before prescribing; Lynkuet also has important drug interactions and is not recommended with moderate or severe liver impairment or end-stage kidney disease. These are not complete safety summaries; read the full labels and discuss your own risks with your clinician.

Other options include certain antidepressants and cognitive behavioral therapy. The right choice depends on your symptoms, health history, other medicines and preferences. “Nonhormonal” does not mean “no monitoring” or “no risks.”

Four questions for your next visit

1. Has my specific medicine’s label changed, and what does that mean for me?
2. Given whether I have a uterus, do I need protection for the uterine lining?
3. How do my age, time since menopause and medical history affect my options?
4. If hormones are not suitable, which nonhormonal approach fits—and what monitoring does it require?

Where Kindr fits

At Kindr Health, menopause care is clinician-led. The conversation starts with your symptoms, history and goals—not an assumption that one treatment is right for everyone.

Updated labels can support better conversations. Research can help improve future care. Neither replaces a thoughtful discussion about what makes sense for you today.

This article is for general education, not medical advice. Talk with your clinician before starting, stopping or changing medication.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 8, 2026